Lupin Partners with Celnova for Drug Distribution in South America
By Rediff Money Desk, New Delhi Sep 27, 2024 18:45
Lupin's subsidiary has partnered with Celnova Pharma to distribute NaMuscla, a drug for non-dystrophic myotonic disorders, in Argentina and Colombia. The partnership aims to provide innovative treatment options for patients with these rare neuromuscular disorders.
New Delhi, Sep 27 (PTI) Lupin on Friday said its subsidiary has signed a pact with Celnova Pharma for the distribution of a drug in Argentina and Colombia.
The distribution pact is for a drug indicated for the treatment of non-dystrophic myotonic disorders. Lupin Atlantis Holdings SA has inked the pact with Celnova.
As per the pact, Celnova will commercialise NaMuscla in Argentina and Colombia, for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders, Lupin said in a statement.
NaMuscla is the first and the only licensed product in Europe for this indication, it added.
NDM disorders are a group of rare, inherited neuromuscular disorders, characterized by the inability to relax muscles due to voluntary contraction resulting in myotonia or muscle stiffness.
NaMuscla reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients.
NaMuscla, which has been designated orphan drug status in Europe and US, received EU marketing authorisation in December 2018.
As per the agreement, Celnova will be the exclusive distributor of NaMuscla in Argentina and Colombia, and drive the registration, importation, storage, and sales, Lupin said.
The Mumbai-based company will manufacture and supply the finished products to Celnova, it added.
"This is aligned to our commitment of meeting the needs of NDM patients by creating tailor-made solutions for each market, working with health authorities, healthcare providers, patient advocacy groups to help patients suffering from myotonia diseases," said Fabrice Egros, President Corporate Development and Growth Markets, Lupin.
Celnova CEO Juan Marrone said the collaboration addresses a significant unmet need of those living with non-dystrophic myotonic disorders, offering an innovative treatment option that can greatly improve quality of life.
The distribution pact is for a drug indicated for the treatment of non-dystrophic myotonic disorders. Lupin Atlantis Holdings SA has inked the pact with Celnova.
As per the pact, Celnova will commercialise NaMuscla in Argentina and Colombia, for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders, Lupin said in a statement.
NaMuscla is the first and the only licensed product in Europe for this indication, it added.
NDM disorders are a group of rare, inherited neuromuscular disorders, characterized by the inability to relax muscles due to voluntary contraction resulting in myotonia or muscle stiffness.
NaMuscla reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients.
NaMuscla, which has been designated orphan drug status in Europe and US, received EU marketing authorisation in December 2018.
As per the agreement, Celnova will be the exclusive distributor of NaMuscla in Argentina and Colombia, and drive the registration, importation, storage, and sales, Lupin said.
The Mumbai-based company will manufacture and supply the finished products to Celnova, it added.
"This is aligned to our commitment of meeting the needs of NDM patients by creating tailor-made solutions for each market, working with health authorities, healthcare providers, patient advocacy groups to help patients suffering from myotonia diseases," said Fabrice Egros, President Corporate Development and Growth Markets, Lupin.
Celnova CEO Juan Marrone said the collaboration addresses a significant unmet need of those living with non-dystrophic myotonic disorders, offering an innovative treatment option that can greatly improve quality of life.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 10.67 (+ 2.50)
- 69776634
- Spicejet Ltd.
- 58.71 ( -5.06)
- 51299261
- Standard Capital
- 1.52 (+ 9.35)
- 46654145
- GACM Technologies
- 0.95 ( -5.00)
- 28597471
- GTL Infrastructure
- 2.53 (+ 4.98)
- 19162474
MORE NEWS
Gold Duty Cut: Sisters Can Now Buy Heavier...
Union Commerce Minister Piyush Goyal says the gold duty cut will allow women to buy...
SCOPE Launches USD 50 Million Venture Capital Fund
SCOPE, a startup networking platform, has received SEBI approval to launch a USD 50...
Karnataka Approves Rs 4,071 Crore Projects: Job...
Karnataka's State-Level Single Window Clearance Committee approves 88 projects worth Rs...